TROV TrovaGene Inc.

-0.01  -0%
Previous Close 3.11
Open 3.13
Price To Book 1.68
Market Cap 16260216
Shares 5,245,231
Volume 46,588
Short Ratio
Av. Daily Volume 772,829

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 presentation at ESMO September 27, 2019.
Onvansertib (PCM-075)
Acute Myeloid Leukemia (AML)
Phase 1/2 presentation at ESMO September 27, 2019.
Onvansertib (PCM-075) and Zytiga
Prostate cancer

Latest News

  1. Could TrovaGene, Inc.'s (NASDAQ:TROV) Investor Composition Influence The Stock Price?
  2. Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital
  3. Trovagene: 1Q Earnings Snapshot
  4. Trovagene Announces First Quarter 2019 Results and Highlights
  5. Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML
  6. Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib
  7. Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
  8. Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
  9. Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels
  10. Trovagene Receives Approximately $3.0 Million From Exercise of Warrants
  11. A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?
  12. Trovagene Regains Compliance with Nasdaq Listing Requirements
  13. What Should We Expect From TrovaGene, Inc.’s (NASDAQ:TROV) Earnings Over The Next Few Years?
  14. TrovaGene News: Why TROV Stock Is Skyrocketing Today
  15. Trovagene Announces Fourth Quarter and Full-Year 2018 Results
  16. Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting
  17. Trovagene, Inc. Announces Reverse Stock Split
  18. Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference
  19. Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)
  20. Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer